Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to ... yet another potential use for the versatile drug class. The small, 48-subject study – published in the journal JAMA ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or overweight after 36 ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome ... and improvement in some cholesterol parameters, with a very small increase in heart rate.

It has similar efficacy to other GLP1 agonists ... for CV events probably combine to make GLP-1 RAs protective against CV events. However, recent small studies on both animals and humans have ...

The MHRA said it had received a “very small number of reports of aspiration during a surgical procedure associated with GLP-1 or dual GIP/GLP-1 receptor agonists, including one case that resulted in ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

“GLP-1 agonists ... weight using GLP-1 agonist drugs but are planning to discontinue the treatment. RDX-002, Response Pharmaceuticals’ lead candidate, is an investigational first-in-class, potent, ...

The toxic bite of a Gila monster can kill a human, but a specific ingredient in the cocktail of the lizard's venom is the ...